Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Nathalie Meneveau"'
Autor:
Chloé Drozd, Elsa Curtit, Valérie Gillet, Quentin Jacquinot, Nathalie Meneveau, Fabienne Mougin
Publikováno v:
Cancers, Vol 16, Iss 12, p 2241 (2024)
Cancer is associated with increased muscle weakness, reduced physical functioning, increased fatigue, but also sleep disturbances, including insomnia, that affect quality of life (QoL). Physical activity demonstrated benefits on functional capacity,
Externí odkaz:
https://doaj.org/article/16ede207024d4d3fbd3c7bb05701391a
Autor:
Chloé Drozd, Elsa Curtit, Quentin Jacquinot, Charlène Marquine, Laura Mansi, Loïc Chaigneau, Erion Dobi, Julien Viot, Guillaume Meynard, Marie-Justine Paillard, Morgan Goujon, Pauline Roux, Dewi Vernerey, Valérie Gillet, Hubert Bourdin, Silvio Galli, Nathalie Meneveau, Fabienne Mougin
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Up to 70% of breast cancer patients report symptoms of insomnia during and after treatment. Despite the ubiquity of insomnia symptoms, they are under-screened, under-diagnosed and poorly managed in breast cancer patients. Sleep me
Externí odkaz:
https://doaj.org/article/5473dfa5db4749b08b82dda664fb277d
Autor:
Zohair Selmani, Chloé Molimard, Alexis Overs, Fernando Bazan, Loic Chaigneau, Erion Dobi, Nathalie Meneveau, Laura Mansi, Marie-Justine Paillard, Guillaume Meynard, Julien Viot, Marie-Paule Algros, Christophe Borg, Jean-Paul Feugeas, Xavier Pivot, Jean-Luc Prétet, Elsa Curtit
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Breast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype DX test was designed for ER+/HER2− early-stage breast cancers to help adjuvant chemotherapy decision by providing a Recurrent Score (RS). RS measures
Externí odkaz:
https://doaj.org/article/fb403b3f72cf4ec7a11eabb6e2d69679
Autor:
Quentin Jacquinot, Nathalie Meneveau, Antoine Falcoz, Malika Bouhaddi, Pauline Roux, Bruno Degano, Marion Chatot, Elsa Curtit, Laura Mansi, Marie-Justine Paillard, Fernando Bazan, Loïc Chaigneau, Erion Dobi, Guillaume Meynard, Dewi Vernerey, Xavier Pivot, Fabienne Mougin
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
BackgroundTrastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive breast cancer (BC). Although it improves cancer outcomes, trastuzumab. can lead to cardiotoxicity. Physical exercise is a safe and effective sup
Externí odkaz:
https://doaj.org/article/b99f6aa41f744bdf96b74aa0e763ad8d
Autor:
Quentin Jacquinot, Nathalie Meneveau, Marion Chatot, Franck Bonnetain, Bruno Degano, Malika Bouhaddi, Gilles Dumoulin, Dewi Vernerey, Xavier Pivot, Fabienne Mougin
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-11 (2017)
Abstract Background The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is a poor prognosis. Trastuzumab improves overall survival but is associated with cardiotoxicity, especially a decline in left ventricular ejec
Externí odkaz:
https://doaj.org/article/51125522a32e4989bcba30586fbc60c4
Autor:
Christophe Borg, Laura Mansi, Cristian Villanueva, Stefano Kim, Elsa Curtit, Oumelkheir Djoumakh, Amélie Anota, Guillaume Eberst, Sophie Paget-Bailly, Guillaume Mouillet, Antoine Falcoz, Marine Jary, Hamadi Almotlak, Xavier Pivot, Olivier Adotevi, J. Fritzsch, Astrid Pozet, Nathalie Meneveau, Fabien Calcagno, Angélique Vienot, Virginie Westeel, P. Jacoulet
Publikováno v:
Quality of Life Research. 30:3255-3266
Routine Electronic Monitoring of Health-Related Quality of Life (HRQoL) (REMOQOL) in clinical care with real-time feedback to physicians could help to enhance patient-centered care. We evaluated the feasibility of REMOQOL in the French context in the
Autor:
Zohair Selmani, Chloé Molimard, Alexis Overs, Fernando Bazan, Loic Chaigneau, Erion Dobi, Nathalie Meneveau, Laura Mansi, Marie-Justine Paillard, Guillaume Meynard, Julien Viot, Marie-Paule Algros, Christophe Borg, Jean-Paul Feugeas, Xavier Pivot, Jean-Luc Prétet, Elsa Curtit
Breast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype DX® test was designed for ER+/HER2- early-stage breast cancers to help adjuvant chemotherapy decision by providing a Recurrent Score® (RS®). RS® measures th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1067abffda23dae2694a335b0cc9c45
https://doi.org/10.21203/rs.3.rs-677106/v1
https://doi.org/10.21203/rs.3.rs-677106/v1
Autor:
Zohair Selmani, Chloé Molimard, Alexis Overs, Fernando Bazan, Loic Chaigneau, Erion Dobi, Nathalie Meneveau, Laura Mansi, Marie-Justine Paillard, Guillaume Meynard, Julien Viot, Marie-Paule Algros, Christophe Borg, Jean-Paul Feugeas, Xavier Pivot, Jean-Luc Prétet, Elsa Curtit
Publikováno v:
Scientific reports. 12(1)
Breast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype DX test was designed for ER+/HER2− early-stage breast cancers to help adjuvant chemotherapy decision by providing a Recurrent Score (RS). RS measures the expr
Publikováno v:
Médecine du Sommeil. 19:32-33
Autor:
Marie-Paule Algros, Jean-Luc Prétet, Laura Mansi, Christophe Borg, Jean-Paul Feugeas, Nathalie Meneveau, Zohair Selmani, Elsa Curtit, Chloé Molimard, Loic Chaigneau, Alexis Overs, Marie-Justine Paillard, Julien Viot, Fernando Bazan, Erion Dobi, Guillaume Meynard, Xavier Pivot
Background: Breast cancers expressing high levels of Ki67 are associated with poor outcomes. To provide individualized patient care, reliability of prognostic and predictive information deriving from Ki67 assessment is essential. Oncotype DX® test w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c28613e30f4910f45a01776fff80982
https://doi.org/10.21203/rs.3.rs-525965/v1
https://doi.org/10.21203/rs.3.rs-525965/v1